Pfizer’s Obesity Pipeline Poised to Challenge Novo Nordisk
Pfizer is quietly building a GLP-1 obesity pipeline that could alter the competitive landscape, while investors seek ...
Examine the worst drawdowns for Dividend Aristocrats ETF and extract lessons to strengthen risk management in your portfolio.
9,644 articlesPfizer is quietly building a GLP-1 obesity pipeline that could alter the competitive landscape, while investors seek ...
Markets are sizing Coca-Cola for a two-year path as AI-driven capital shifts reshape sectors. A fresh price predictio...
UnitedHealth stock has lagged in 2026, raising questions about its earnings, growth, and risks. This deep-dive breaks...
Costco stock has delivered impressive long-term results, but a disciplined approach matters. This guide breaks down t...
In a market crowded with megacaps, an overlooked energy stock may offer outsized upside in 2026. Learn how to spot th...
With housing payments rising and rates lingering near multi-year highs, five categories of monthly dividend investmen...
Strategy faces a tough trade-off: use cash to back STRC dividends and buy Bitcoin, or raise fresh capital that dilute...
Investors chasing income may be chasing sky-high yields that hide fragile payouts. Three BDCs illustrate growing payo...
When a blue-chip pharma stock falls 25%, many investors wonder if it's time to buy. This guide breaks down how to ass...
March is a pivotal time for industrial stocks as infrastructure and defense themes collide with energy transition dem...
Pfizer has reset its growth trajectory with big bets on Seagen and a future GLP-1 drug. This analysis breaks down wha...
Cash flow from senior housing and warehouse REITs is holding steady even as refinancing costs rise. The payout outloo...